手机版 English 帮助中心
外文文献知网节
文献信息节点
基本信息 摘要 关键词 核心评价 相关文献
Journal | [J] 医学前沿 Volume 7, Issue 4. 2025.
肝癌标志物的最新研究进展
作者 : 陆 新程, 唐 军*
DOI: 10.18686/yxqy.v7i4.23030
全部来源
获取全文
摘要 / Abstract
肿瘤标志物在肝癌的早期诊断、疗效评估、预后预测以及复发监测中发挥着至关重要的作用。理想的肿瘤标志物 应具有高敏感性和特异性，能够反映肿瘤的动态变化，并为治疗决策提供指导。近年来，随着分子生物学技术和液体活检 技术的发展，肝癌肿瘤标志物的研究取得了显著进展，从传统的蛋白质标志物到循环核酸、外泌体等多组学标志物，为肝 癌的精准医疗提供了新的机遇。多组学标志物的应用不仅实现了肝癌分子分型的精细化，更推动了靶向治疗和免疫治疗的 精准选择。
关键词 / Keywords
肝癌；肿瘤标志物；外泌体；精准医疗
Related articles / 相关文献
相似文献
作者发文
机构发文
关键词分析
相似文献（说明：与本文内容较接近的文献）
  • [1] Wei Zhang，Di Wu，et al. Development and evaluation
  • of a nomogram prediction model for invasion and metastasis in
  • primary liver cancer based on serum CD147 and IL-6 [J].Frontiers
  • in Oncology，2025，15：1524765.
  • [2]Chivu-EconomescuM, NeculaL, MateiL, et al. Clinical
  • app-lications of liquid biopsy in gastric cancer[J]. Front Med
  • (Lausanne), 2021, 8:749250.
  • [3]PivaVM, De GrandisMC, ZuinIS, et al. ctDNA as
  • promising tool for the assessment of minimal residual disease
  • (MRD) and the need of an adjuvant treatment in gastroesophageal
  • adenocarcinoma[J]. Updates Surg, 2023, 75(2):305-312.
  • [4]Felismino, T., Martins, L., Barroso, M. et al. Neutrophil-
  • to-Lymphocyte Ratio (NLR) as a Predictive Biomarker in
  • Advanced Hepatocellular Carcinoma Treated with First-Line
  • Immunotherapy. J Gastrointest Canc 56, 175 (2025).
  • [5]Zhang T Q, Geng Z J, Zuo M X, et al. Camrelizumab
  • (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and
  • hepatic artery infusion chemotherapy for hepatocellular carcinoma
  • in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II
  • study[J]. Signal transduction and targeted therapy, 2023, 8(1): 413.
  • [6] Kudo M, Ren Z, Guo Y, et al. Transarterial
  • chemoembolisation combined with lenvatinib plus pembrolizumab
  • versus dual placebo for unresectable, non-metastatic
  • hepatocellular carcinoma (LEAP-012): a multicentre, randomised,
  • double-blind, phase 3 study[J]. The Lancet, 2025, 405(10474):
  • 203-215.
  • [7] Zhu, Yajing; Zhang，et al. Pan Gene expression profile
  • of anoikis reveals new subtypes of liver cancer and discovery of
  • therapeutic targets and biomarkers. Scientific Reports, 2025, Vol
  • 15, Issue 1, p1.
  • [8] Zhen SH，Cheng M，Tao YB，et al. Deep learning for
  • accurate diagnosis of liver tumor based on magnetic resonance
  • imaging and clinical data［J］.Front Oncol，2020，10：680.
  • [9]Circulating tumour DNA methylation markers for diagnosis
  • and prognosis of hepatocellular carcinoma[J].Nature Materials,
  • 2017, 16(11):1155.
  • [10]Ding J, Zou X, et al. ZBED4: A Prognostic Biomarker
  • and Therapeutic Target in Hepatocellular Carcinoma. J Hepatocell
  • Carcinoma. 2025;12:1873-1892.
  • [11] R a n j i t h B a l a k r i s h n a n , R a j a s e k a r a n , e t a l .
  • Subbarayan,Circulating miR-542-3p as a Prognostic Marker
  • forHepatocellular Carcinoma: A Systematic Review andMeta-
  • Analysis. Journal of Cellular and Molecular Medicine. 29, no. 14
  • (2025): e70748.
  • [12]Guo, X., Zhao, Z., Zhu, L. et al. The evolving landscape
  • of biomarkers for systemic therapy in advanced hepatocellular
  • carcinoma. Biomark Res 13, 60 (2025).
《中国学术期刊(光盘版)》电子杂志社有限公司 KDN平台基础技术由KBASE 11.0提供
© 2014-2018中国知网(CNKI) 京公网安备11010802020460号 经营性网站备案信息 互联网出版许可证 新出网证(京)字271号 京ICP证040431号